| ¿µ¹® | oral administration | ÇÑ±Û | °æ±¸º¹¿ë |
|---|---|---|---|
| ¼³¸í | ¾àÀ» Åõ¿©ÇÏ´Â ¹æ¹ý¿¡´Â ¿©·¯ °¡Áö°¡ ÀÖ´Ù. Å©°Ô ³ª´©¾î º¸¸é, ÀÔÀ» °ÅÃÄ À§Ã¢Àڰ踦 ÅëÇØ ³Ö´Â ¹æ¹ý°ú À§Ã¢Àڰ踦 ÅëÇÏÁö ¾Ê°í ¹Ù·Î Ç÷¾×À¸·Î ³Ö´Â ¹æ¹ýÀÌ ÀÖ´Ù. À§Ã¢Àڰ踦 ÅëÇÏÁö ¾Ê´Â ¹æ¹ýÀ¸·Î °¡Àå ÈçÇÑ ¹æ¹ýÀº Áֻ縦 ÀÌ¿ëÇÏ´Â ¹æ¹ýÀÌ´Ù. ÇÏÁö¸¸, À̿ܿ¡ Ç×¹®À» ÅëÇØ ³Ö´Â Á¾à½Ä¹æ¹ý°ú Çô¹Ø¿¡ ³Ö´Â Çô¹ØÅõ¿©¹ýµµ ÀÖ´Ù. ±×·¯³ª ´ëºÎºÐÀÇ ¾àÁ¦´Â °æ±¸º¹¿ëÀ» ÇÏ°Ô µÈ´Ù. °æ±¸º¹¿ë¿¡ ´ëÇÑ ¾àÀÚ´Â p.o.(per oral)·Î Ç¥±âÇÑ´Ù. °æ±¸º¹¿ëÁ¦ÀÇ ´ÜÁ¡Àº º¹¿ëÇÑ ¾àÁ¦°¡ À§Ã¢ÀÚ°ü°è¸¦ °ÅÄ¡¸é¼ »ç¶÷¸¶´Ù °¢±â ´Ù¸¥ Èí¼öÁ¤µµ¿Í ´ë»çÁ¤µµ¸¦ °ÅÄ¡°Ô µÇ¹Ç·Î ÀÏÁ¤ÇÑ ³óµµÀ¯Áö°¡ ¾î·Æ´Ù´Âµ¥ ÀÖ´Ù. ¶ÇÇÑ °æ±¸º¹¿ëÁ¦ÀÇ ¸ð¾çÀÌ Ä¸½¶ÇüÀÎÁö, ȤÀº °¡·çÇüÀÎÁö¿¡ µû¶ó¼µµ °°Àº ¾àÀÌÁö¸¸, ¼·Î ´Ù¸¥ È¿°ú¸¦ ³ªÅ¸³¾ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | oral cavity | ÇÑ±Û | ±¸° |
|---|---|---|---|
| ¼³¸í | ÀÔÀ» ¹ú¿©¼ ÀÔ¼Ó¿¡¼ º¼ ¼ö ÀÖ´Â °ø°£À¸·Î ÀÔõÀå, Æíµµ, ¸ñÁ¥À» º¼ ¼ö ÀÖ´Ù. ![]() |
||
| ¿µ¹® | oral cavity | ÇÑ±Û | ÀÔ¾È |
|---|---|---|---|
| ¼³¸í | ÀÔÀ» ¹ú¿©¼ ÀÔ¼Ó¿¡¼ º¼ ¼ö ÀÖ´Â °ø°£À¸·Î ÀÔõÀå, Æíµµ, ¸ñÁ¥À» º¼ ¼ö ÀÖ´Ù. |
||
| ORS | olfactory reference syndrome; oral rehydration solution; oral surgery, oral surgeon; Orthopaedic Res... |
|---|---|
| MDIPT | Multicenter Diltiazem Postinfarction Trial |
| PREDICT | Prospective Randomized Evaluation of Diltiazem CD Trial |
| Mal | malate; malfunction; malignancy |
| MD | Doctor of Medicine [Lat. Medicinae Doctor]; magnesium deficiency; main duct; maintenance dose; major... |
| MDH | L-Malate dehydrogenase |
|---|---|
| mMDH | Mitochondrial malate dehydrogenase |
| MS | malate synthase |
| D | Diltiazem |
| DIL | Diltiazem |
naso-oral
| diltiazem | <chemical> A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of the calcium ion in membrane functions. It is also teratogenic. Pharmacological action: antihypertensive agents, calcium channel blockers, cardiovascular agents, teratogens, vasodilator agents. Direct, potent negative chronotrope with only mild negative inotropic effect; slows conduction in AV node; coronary vasodilation with less systemic vasodilation than verpamil. Chemical name: 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- Uses: Control ventricular response with atrial fibrillation Dose: 0.25 mg/kg IV over 2 minutes May repeat at 0.35 mg/kg after 15 minutes. Maintenance infusion at 5 - 15 mg/hr. Potential complications: Less hypotension than with verapamil since less vasodilation and myocardial depression; bradycardia; may exacerbate AV block; synergistic interaction with beta blockers; relatively contraindicated with congestive heart failure. Note: Diltiazem can accelerate heart rate and decrease blood pressure, especially in patients with Wolff-Parkinson-White or wide-complex tachycardia. (15 Mar 2000) |
|---|---|
| diltiazem hydrochloride | 1,5-Benzothiazepin-4(5H)one,3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-monohydrochloride, (+)-cis-;a calcium channel blocking agent used as a coronary vasodilator and antihypertensive. (05 Mar 2000) |
| malate | <chemistry> A salt of malic acid. Origin: L. Malum apple: cf. F. Malate. See Malic. Source: Websters Dictionary (01 Mar 1998) |
| malate-aspartate shuttle | A mechanism for the transfer of NADH reducing equivalents from the cytosol into the mitochondria using two isozymes of malate dehydrogenase and aspartate transaminase. (05 Mar 2000) |
| malate ATP lyase | <chemical> Composed of malyl-CoA synthetase (EC 6.2.1.9) and malyl-CoA lyase (EC 4.3.24) Synonym: malate lyase (26 Jun 1999) |
| malate carboxy-lyase | <enzyme> Decarboxylates l-malic acid to l-lactic acid and co2 with traces of pyruvic acid Registry number: EC 4.1.1.- (26 Jun 1999) |
| malate-condensing enzyme | <enzyme> An important enzyme in the glyoxylic acid cycle which reversibly catalyses the synthesis of l-malate from acetyl-CoA and glyoxylate. Chemical name: L-Malate glyoxylate-lyase (CoA-acetylating) Registry number: EC 4.1.3.2 (12 Dec 1998) |
| malate dehydrogenase | <enzyme> An enzyme that catalyses the conversion of (s)-malate and NAD+ to oxaloacetate and NADH. Chemical name: (S)-Malate:NAD+ oxidoreductase Registry number: EC 1.1.1.37 (12 Dec 1998) |
| malate oxidase | <enzyme> Fad-dependent Registry number: EC 1.1.3.3 (26 Jun 1999) |
| malate permease | <chemical> Isolated from leuconostoc oenos. Synonym: mlep gene product, malate transporter (26 Jun 1999) |
| malate synthase | <enzyme> An important enzyme in the glyoxylic acid cycle which reversibly catalyses the synthesis of l-malate from acetyl-CoA and glyoxylate. Chemical name: L-Malate glyoxylate-lyase (CoA-acetylating) Registry number: EC 4.1.3.2 (12 Dec 1998) |
| administration, oral | The giving of drugs, chemicals, or other substances by mouth. (12 Dec 1998) |
| cancer, oral | Cancer of the mouth area. A sore in the mouth that does not heal can be a warning sign of oral cancer. A biopsy is the only to know whether as abnormal area in the oral cavity is cancer. Oral cancer is caused by tobacco (smoking and chewing) and alcohol use. Surgery to remove the tumour in the mouth is the usual treatment for patients with oral cancer. (12 Dec 1998) |
| candidiasis, oral | Infection of the mucous membranes of the mouth by a fungus of the genus candida. (12 Dec 1998) |
| canine oral papilloma | Warts affecting mucous membranes of young dogs; caused by a papillomavirus. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|